---
{"dg-publish":true,"permalink":"/Reference notes/Readwise/Tweets/Challenges in Medicine.../"}
---

# ğŸ˜±Challenges in MedicineğŸ˜±...

![rw-book-cover](https://pbs.twimg.com/profile_images/1566858765609193486/5rq5awvk.jpg)

## Metadata
- Author: [[@NicoGagelmann on Twitter\|@NicoGagelmann on Twitter]]
- Full Title: ğŸ˜±Challenges in MedicineğŸ˜±...
- Category: #tweets
- URL: https://twitter.com/NicoGagelmann/status/1663383303821438976

## Highlights
- ğŸ˜±Challenges in medicineğŸ˜±
  Thrombotic microangiopathy (TMA)
  A short ğŸ§µ#MedTwitter
  1/16 
  ![](https://pbs.twimg.com/media/FxVpejSWIAECnnw.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383303821438976))
- Intro:
  TMA syndromes are extraordinarily diverseâ—ï¸
  They may be
  -hereditary or acquired
  -occur in children and adults
  -onset can be sudden or gradual
  BUT
  despite their diversity, they are united by common, defining clinical and pathological features
  2/16 https://t.co/Ep6ANz4Qr6 ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383315133485058))
- A short history of everything TMA
  3/16 
  ![](https://pbs.twimg.com/media/FxVrL_OXwAEwF07.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383318228811778))
- Features:
  -Thrombopenia
  ğŸ‘‰platelet aggregation & thrombi
  -microangiopathic haemolytic anaemia (MAHA)
  ğŸ‘‰RBC fragmentation (schistocytes)
  -end organ damage
  -LDHâ¬†ï¸
  ğŸ‘‰tissue ischemia & cell lysis
  -haptoglobinâ¬‡ï¸
  ğŸ‘‰binds to free Hb, hemolysis
  -Coombs generally negative, PT/aPTTâ¬‡ï¸
  4/16 
  ![](https://pbs.twimg.com/media/FxVuXuzXwAA8gPO.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383321538093058))
- Pathology:
  -For all primary TMA syndromes the same
  - -renal arteriole occlusion with endotheliosis as well as lumen and vessel-wall fibrin
  - -Proliferation in the myocyte layer (â€œonion skinningâ€) may also be present 
  5/16 
  ![](https://pbs.twimg.com/media/FxVvC_VWwAIApjv.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383324306419714))
- Think first before you act:
  Before you start sophisticated lab tests and hypotheses, exclude common causes of MAHA and thrombocytopeniaâ—ï¸
  Remember, any condition associated with DIC can occur with MAHA and thrombocytopenia
  ğŸ‘‰rule out first
  https://t.co/qaQrTTRHYf
  6/16 
  ![](https://pbs.twimg.com/media/FxVwYLDWwAI_BLC.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383327359868929))
- Evaluate MAHA and thrombopenia:
  -severity of kidney injury as distinguishing feature
  -severe acute kidney injury
  ğŸ‘‰consider complement-mediated (acquired/hereditary)
  -idiopathic disease in + 20%
  -TTP is also called ADAMTS13 deficiencyâ€“mediated TMA
  7/16 
  ![](https://pbs.twimg.com/media/FxV0wdeXwAE2Gqm.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383330560122881))
- Thrombotic thrombocytopenic purpura:
  -rare systemic form of TMA 
  ğŸ‘‰severe deficiency in ADAMTS13
  ğŸ‘‰disintegrin + metalloprotease with thrombospondin type 1 motif 13, which cleaves von Willebrand factor 
  For more, I refer to the legend @nihardesai7 https://t.co/fQjYSBBcg5
  8/16 
  ![](https://pbs.twimg.com/media/FxV1UkJX0AAVoXc.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383341104496641))
- Complement-mediated aHUS:
  -0.4 cases per Mio per year
  -acquired or inherited defects in the alternative pathway
  -Extra-renal manifestations in 10-20%
  -AKI more prominent than in TTP
  -Genetic screening (CFH, CFI, C3, CFB, CD46, CFHR1) is essential, incl DGKE & MMACHC
  9/16 
  ![](https://pbs.twimg.com/media/FxV17orWwAMCP5W.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383344493613056))
- Shigatoxin-associated TMA:
  -most common form, mainly occurring in children <5â€‰years
  -accounts for 90% of cases of HUS in children
  -transmission
  ğŸ‘‰undercooked meat, unpasteurised dairy produce, direct contact, ingesting contaminatedğŸ¥¦ğŸ…
  -majority is self-limiting
  10/16 
  ![](https://pbs.twimg.com/media/FxV3s09XoAYLbAU.png) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383347295395840))
- Pregnancy-associated TMA:
  -Pregnancy + postpartum high-risk periods for TTP and complement-mediated aHUSâ—ï¸
  -typically in the 2nd + 3rd trimesters
  -cause: maybe VWF productionâ¬†ï¸
  -experience of caplacizumab limited
  For moreğŸ‘‰legend @nihardesai7 
  11/16
  https://t.co/QhYx9OJcQT ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383350340468737))
- Transplant-associated (TA-) TMA:
  -high mortalityâ—ï¸
  -etiology is myriad
  -~8% of BMT patients
  -historically, plasma exchange was mainstay of treatment
  BUT
  -with recognition that ADAMTS13 levels in TA-TMA are mostly normal, strategies have shifted away from this approach
  12/16 
  ![](https://pbs.twimg.com/media/FxV7AWFXsAMsndX.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383352953434112))
- TA-TMA treatment:
  -Elucidation of complement in development of TA-TMA shifted treatment toward terminal complement inhibition with eculizumab and MASP-2 inhibition with narsoplimab
  -Prospective data on eculizumab still limited to children
  -more evidence needed
  13/16 
  ![](https://pbs.twimg.com/media/FxV74NOWYAAqTSR.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383355805540352))
- Narsoplimab for TA-TMA:
  -IV once weekly for 4-8 weeks
  -Response rate: 61%, similar across subgroups
  -Improvement in organ function in 74%
  -100-day survival after TA-TMA diagnosis was 94% in responders
  14/16 
  ![](https://pbs.twimg.com/media/FxV9SHaXwAIciNH.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383358708097025))
- Autoimmune TMA:
  -SLE, scleroderma renal crisis or catastrophic antiphospholipid syndrome (CAPS)
  -Case reports describe use of eculizumab in SLE-TMA
  -~30% of CAPS show renal TMA with 36% morality ğŸ‘‰glucocorticoids, anticoagulants + IVIG
  For moreğŸ‘‰legend @PanktiMehta24 
  15/16 
  ![](https://pbs.twimg.com/media/FxWD9-_XgAEVm-6.jpg) ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383361623146496))
- Summary of TMA:
  â—ï¸Array of manifestations, CHALLENGING
  â—ï¸High morbidity + mortality
  â—ï¸Renal involvement is common
  â—ï¸Suspect: MAHA, thrombopenia
  â—ï¸rule out other causes
  â—ï¸rapid assessment, diagnosis + treatment essential
  â—ï¸TA-TMA very serious
  â—ï¸Eculizumab, narsoplimab new options https://t.co/jSsRscN7Wn ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383376949043201))
- References and resources:
  https://t.co/CtZFb2OpNz
  https://t.co/MZ2VN56cyi
  https://t.co/lBzSYmuUhn
  https://t.co/3MKKIma7O5
  https://t.co/Ao1dRanTs4
  https://t.co/0T6KLDeySW https://t.co/EMFFHJqGcj ([View Tweet](https://twitter.com/NicoGagelmann/status/1663383386868555781))
